Australian pre-clinical drug development company Nyrada (ASX:NYR) has announced the appointment of Cameron Jones as its chief financial officer.
Mr Jones replaces Shawn van Boheemen who oversaw the Company’s initial public offering and ASX-listing process, operating under a shared services agreement with major Nyrada shareholder Noxopharm.
He is the managing director of Bio101 and acts as CFO and company secretary for several ASX listed and venture capital life science companies.
Bio101 is a financial services firm providing outsourced CFO, tax and company secretarial solutions to the life science sector. Mr Jones is a chartered accountant and Nyrada said he brings valuable industry knowledge to the company.
Nyrada specialises in the development of novel small molecule drugs to treat cardiovascular, neurological and inflammatory diseases. The company has two main programs - a cholesterol-lowering drug and a drug to treat brain injury, specifically traumatic brain injury and stroke.